Rethinking 'academic' drug discovery: the Manchester Institute perspective

Allan M Jordan; Ian D Waddell; Donald J Ogilvie

doi:10.1016/j.drudis.2014.12.011

Rethinking 'academic' drug discovery: the Manchester Institute perspective

Allan M Jordan, Ian D Waddell, Donald J Ogilvie

Cancer Research UK Manchester Institute

Research output: Contribution to journal › Article › peer-review

Abstract

The contraction in research within pharma has seen a renaissance in drug discovery within the academic setting. Often, groups grow organically from academic research laboratories, exploiting a particular area of novel biology or new technology. However, increasingly, new groups driven by industrial staff are emerging with demonstrable expertise in the delivery of medicines. As part of a strategic review by Cancer Research UK (CR-UK), the drug discovery team at the Manchester Institute was established to translate novel research from the Manchester cancer research community into drug discovery programmes. From a standing start, we have taken innovative approaches to solve key issues faced by similar groups, such as hit finding and target identification. Herein, we share our lessons learnt and successful strategies.

Original language	English
Pages (from-to)	525-35
Number of pages	11
Journal	Drug discovery today
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/j.drudis.2014.12.011
Publication status	Published - May 2015

Keywords

Academies and Institutes
Antineoplastic Agents
Cooperative Behavior
Drug Discovery
England
Humans
Models, Organizational
Molecular Targeted Therapy
Neoplasms
Program Development
Research Personnel
Signal Transduction
Time Factors
Translational Medical Research
Workflow

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2014.12.011

Cite this

@article{431f25af8c474a8bbfd9e1060fa9d32c,

title = "Rethinking 'academic' drug discovery: the Manchester Institute perspective",

abstract = "The contraction in research within pharma has seen a renaissance in drug discovery within the academic setting. Often, groups grow organically from academic research laboratories, exploiting a particular area of novel biology or new technology. However, increasingly, new groups driven by industrial staff are emerging with demonstrable expertise in the delivery of medicines. As part of a strategic review by Cancer Research UK (CR-UK), the drug discovery team at the Manchester Institute was established to translate novel research from the Manchester cancer research community into drug discovery programmes. From a standing start, we have taken innovative approaches to solve key issues faced by similar groups, such as hit finding and target identification. Herein, we share our lessons learnt and successful strategies.",

keywords = "Academies and Institutes, Antineoplastic Agents, Cooperative Behavior, Drug Discovery, England, Humans, Models, Organizational, Molecular Targeted Therapy, Neoplasms, Program Development, Research Personnel, Signal Transduction, Time Factors, Translational Medical Research, Workflow",

author = "Jordan, {Allan M} and Waddell, {Ian D} and Ogilvie, {Donald J}",

year = "2015",

month = may,

doi = "10.1016/j.drudis.2014.12.011",

language = "English",

volume = "20",

pages = "525--35",

journal = "Drug discovery today",

issn = "1878-5832",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - Rethinking 'academic' drug discovery

T2 - the Manchester Institute perspective

AU - Jordan, Allan M

AU - Waddell, Ian D

AU - Ogilvie, Donald J

PY - 2015/5

Y1 - 2015/5

N2 - The contraction in research within pharma has seen a renaissance in drug discovery within the academic setting. Often, groups grow organically from academic research laboratories, exploiting a particular area of novel biology or new technology. However, increasingly, new groups driven by industrial staff are emerging with demonstrable expertise in the delivery of medicines. As part of a strategic review by Cancer Research UK (CR-UK), the drug discovery team at the Manchester Institute was established to translate novel research from the Manchester cancer research community into drug discovery programmes. From a standing start, we have taken innovative approaches to solve key issues faced by similar groups, such as hit finding and target identification. Herein, we share our lessons learnt and successful strategies.

AB - The contraction in research within pharma has seen a renaissance in drug discovery within the academic setting. Often, groups grow organically from academic research laboratories, exploiting a particular area of novel biology or new technology. However, increasingly, new groups driven by industrial staff are emerging with demonstrable expertise in the delivery of medicines. As part of a strategic review by Cancer Research UK (CR-UK), the drug discovery team at the Manchester Institute was established to translate novel research from the Manchester cancer research community into drug discovery programmes. From a standing start, we have taken innovative approaches to solve key issues faced by similar groups, such as hit finding and target identification. Herein, we share our lessons learnt and successful strategies.

KW - Academies and Institutes

KW - Antineoplastic Agents

KW - Cooperative Behavior

KW - Drug Discovery

KW - England

KW - Humans

KW - Models, Organizational

KW - Molecular Targeted Therapy

KW - Neoplasms

KW - Program Development

KW - Research Personnel

KW - Signal Transduction

KW - Time Factors

KW - Translational Medical Research

KW - Workflow

U2 - 10.1016/j.drudis.2014.12.011

DO - 10.1016/j.drudis.2014.12.011

M3 - Article

C2 - 25542353

SN - 1878-5832

VL - 20

SP - 525

EP - 535

JO - Drug discovery today

JF - Drug discovery today

IS - 5

ER -

Rethinking 'academic' drug discovery: the Manchester Institute perspective

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this